Mental Health Clinics in Manchester Center, VT Accepting Medicare
5 Mental Health Clinics found. Showing 1 - 5
 Lesley Brodie, M.d., P.c. Clinic - Adult Mental Health Medicare: Not Enrolled in Medicare Practice Location: 82 Elm Street, Manchester Center, VT 05255 Phone: 802-367-1068 Fax: 802-367-1069 |
Step Ahead Aba Vt Llc Behavioral Analyst Medicare: Not Enrolled in Medicare Practice Location: 106 Center Hill Rd Ste 1007, Manchester Center, VT 05255 Phone: 888-238-1818 |
Kdh Counseling Pllc Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 5188 Main St, Manchester Center, VT 05255 Phone: 802-367-3165 |
Manchester Mental Health Plc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 274 Green Mountain Rd, Manchester Center, VT 05255 Phone: 802-558-9433 |
Joanne Beck, Licsw Clinic - Mental Health Medicare: Medicare Enrolled Practice Location: 19 Green Mountain Rd, Manchester Center, VT 05255 Phone: 802-779-1819 |
News Archive
Mucosis receives € 3M innovation credit line from Dutch Ministry for development of FluGEM influenza vaccine
Dutch vaccine development company Mucosis B.V. announced today that it has received an innovation credit line of approximately € 3 million from Agentschap NL, an agency of the Dutch Ministry of Economic Affairs. Mucosis will use this loan towards the clinical development of its lead product FluGEM™, an influenza vaccine that can be administered by a simple spray in the nose. The loan will be redeemed only if the FluGEM™ clinical development program is concluded successfully.
Advitech to transfer business operations to subsidiary Botaneco Speciality Ingredients
Advitech Inc. announces today its intention to close its office on boulevard Lebourgneuf in Quebec City. Advitech's business operations will be transferred to its subsidiary in Calgary, Botaneco Speciality Ingredients Inc. ("Botaneco"). Following the merger of Advitech and Botaneco in November 2009, this is a significant step towards integrating and optimizing operations of the combined entity.
Octapharma USA launches wilate replacement therapy Web site for von Willebrand Disease
Octapharma USA has launched a comprehensive Web site for wilate® at www.wilateusa.com to provide von Willebrand disease healthcare professionals and patients with easily accessible information, news and updates. The U.S. Food and Drug Administration (FDA) has granted orphan drug exclusivity for wilate® (von Willebrand Factor/Factor VIII Concentrate, Human), the first replacement therapy developed specifically for von Willebrand Disease (VWD).
Estrogen-progestin menopausal hormone therapy associated with high risk of both lobular and tubular breast cancer
Estrogen-progestin menopausal hormone therapy is associated with a more than two-fold higher relative risk of developing lobular cancer or tubular cancer than of developing ductal cancer.
› Verified 6 days ago